CD274 and cancer: Among patients with NSQ cancer, there was a significant difference in PDL-1 expressors levels between 8222 patients with any potentially major druggable variants and 7070 patients without potentially major druggable variants (PDL-1 ≥50%: 718 patients [8.7%] vs 833 patients [11.8%]; PDL-1 1% to <50%: 1045 patients [12.7%] vs 767 patients [10.8%]; PDL-1 <1%: 1985 patients [24.1%] vs 1361 patients [19.2%]; P < .001) (Figure 1A and D).